Cosmos Holdings CEO Greg Siokas Converts an Additional $1.0 Million of Debt into Common Stock at $6.00 Per Share

Rhea-AI Summary

Cosmos Holdings, Inc. (OTCQX: COSM) announced a further reduction of $1.0 million in related party debt, converting it into 166,667 shares of common stock at $6.00 per share. This transaction follows a previous debt reduction of $3.0 million at the same price. CEO Greg Siokas emphasized the conversion strengthens their balance sheet and supports the company's growth and potential uplisting to the Nasdaq. Cosmos specializes in pharmaceuticals and has a broad EU distribution network, aiming to enhance patient outcomes.

Positive

• Debt reduction of $1.0 million enhances financial stability.
• Conversion supports potential uplisting to the Nasdaq Capital Market.
• Strengthening the balance sheet aligns with company growth strategies.

Negative

• None.

The conversion price represents a premium to market

CHICAGO, July 16, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the Company") (OTCQX: COSM), an international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and an extensive, established European Union distribution network, is pleased to announce that Mr. Greg Siokas, Chief Executive Officer, has further reduced the debt of the Company by converting an additional $1.0 million of related party debt personally owed to him in exchange for 166,667 shares of common stock at $6.00 per share on July 13, 2021. This conversion follows the previously announced debt reduction of $3.0 million at $6.00 per share.

Greg Siokas, Chief Executive Officer of Cosmos Holdings, stated, “As stated previously, I strongly believe in Cosmos’ upside potential, and I am committed to supporting its growth in every way I can. This debt-to-equity conversion further strengthens our balance sheet as we grow and build a diversified pharmaceutical company with an established distribution network worldwide. This conversion price represents a premium to market and I took this further step as I strongly believe it is in the best interest of the Company and our shareholders. It also further facilitates our goal of uplisting to the Nasdaq Capital Market.”

About Cosmos Holdings, Inc.

Cosmos Holdings Inc. is an international pharmaceutical company, with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices and an extensive, established EU distribution network. The Company identifies, acquires, develops and commercializes products that improve patients' lives and outcomes and has developed a global distribution platform and is currently expanding throughout Europe, Asia and North America. Cosmos Holdings has offices and distribution centers in Thessaloniki, Greece, Athens, Greece and Harlow, UK. More information is available at www.cosmosholdingsinc.com and www.skypremiumlife.com.

Forward-Looking Statements

With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could”, are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company’s ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic on the Company’s business, operations and the economy in general, and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: COSM@crescendo-ir.com

FAQ

What recent debt conversion did Cosmos Holdings announce?

Cosmos Holdings announced the conversion of $1.0 million of related party debt into 166,667 shares of common stock at $6.00 per share.

How does the recent debt reduction impact COSM's financial outlook?

The debt reduction of $1.0 million is expected to strengthen COSM's balance sheet, supporting future growth and operational stability.

What is the significance of the $6.00 conversion price for COSM shares?

The conversion price of $6.00 represents a premium to the market, reflecting positively on investor confidence in COSM.

What are the company's goals following the debt restructuring?

Cosmos Holdings aims to grow and diversify its pharmaceutical offerings while pursuing an uplisting to the Nasdaq.

How much total debt has Cosmos Holdings reduced recently?

Cosmos Holdings has reduced a total of $4.0 million in related party debt through recent conversions.